雷帕霉素对肺癌细胞mTOR信号通路相关蛋白表达的作用
Effects of Rapamycin on Expression of mTOR Signaling Pathway Relative Protein in Lung Cancer Cell
查看参考文献9篇
|
文摘
|
目的 探讨mTOR信号通路的功能状态与肺癌对雷帕霉素敏感度的关系。方法Western blot检测mTOR信号通路中AKT、S6K1、eIF4E、4E-BP1、P-S6K1蛋白在4种人肺癌细胞株的表达；MTT法检测雷帕霉素对肺癌细胞增殖的抑制情况，将肺癌细胞分为雷帕霉素敏感组和不敏感组，找出与敏感度相关的差异蛋白，用En Vision法检测患者肺癌组织中差异蛋白的表达。结果AKT、S6K1、eIF4E、4E-BP1蛋白在4种肺癌细胞株中均有表达。而P-S6K1在不敏感株中未检测到，在敏感株中呈高表达，为雷帕霉素差异蛋白。P-S6K1在正常肺组织中的阳性表达率为15%(3/20例)，在肺癌组织中的阳性表达率为62%(62/100例)，其中在小细胞肺癌组织中的阳性表达率(81.0%，17/21例)高于非小细胞肺癌组织(59%，45/79例)。结论 在mTOR信号通路相关蛋白中，仅P-S6K1在一定程度上可预测肺癌细胞株对雷帕霉素的敏感度，为一种mTOR靶向抑制剂--雷帕霉素治疗肺癌的差异蛋白。P-S6K1在小细胞肺癌中表达较非小细胞肺癌高，提示在P-S6K1表达率高的小细胞未分化肺癌中应用mTOR靶向抑制剂--雷帕霉素的疗效可能更佳。 |
|
其他语种文摘
|
Objective To investigate the relation between the function state of mTOR signal pathway and rapamycin sensitivity to lung cancer.Methods mTOR signaling pathway protein in 4 lung cancer cell lines(HLAMP, H1299, A549 and PAa)were detected by Western Blot.MTT method was used to determine the inhibitory effect of rapamycin on human lung cancer cell.Lung cancer cell lines were divided into rapamycin sensitive group and non-sensitive group.En Vision method was used to detecte the expression of rapamycin differential protein in 100 lung cancer and 20 lung nonmalignant disease normal lung tissues.Result AKT, S6K1, 4E-BP1, eIF4E were expressed in all human lung cancer cell lines.P-S6K1 was high-level expression in sensitive cell lines, no detection in non-sensitive cell line, and it was arapamycin differential protein.P-S6K1 positive-expression rate was 15%(3/20)in normal lung tissues, and 62%(62/100)in lung cancer, respectively.P-S6K1 positive-expression rate in small cell lung cancer(81%, 17/21)was higher than that in non-small cell lung cancer(59%, 45/79).Conclusion The expression of P-S6K1in human lung cancer cell lines may reflect rapamycin sensitivity to cancer cell to a extent.But other mTOR signaling pathway protein(AKT, S6K1, eIF4E, 4E-BP1)can not reflect rapamycin sensitivity to lung cancer cell.P-S6K1 isarapamycin differential protein.The expression of P-S6K1 in small cell lung cancer is much higher than that in non-samll cell lung cancer.The results suggest the better clinical effect of mTOR inhibitor-rapamycin in small cell lung cancer. |
|
来源
|
肿瘤防治研究
,2011,38(10):1105-1108 【扩展库】
|
|
关键词
|
肺癌
;
雷帕霉素
;
mTOR
|
|
地址
|
1.
广州医学院第二附属医院肿瘤科, 广州, 510260
2.
中山大学肿瘤防治中心
|
|
语种
|
中文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
1000-8578 |
|
学科
|
肿瘤学 |
|
基金
|
广州市教育局科技基金资助项目
;
广东省医学科学技术研究基金
|
|
文献收藏号
|
CSCD:4348557
|
参考文献 共
9
共1页
|
|
1.
Bjomsti M A. The TOR pathway: a target for cancer therapy.
Nat Rev Cancer,2004,4(5):335-348
|
CSCD被引
4
次
|
|
|
|
|
2.
Asano T. The Rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation.
Biochem Biophys Res Commun,2005,331(1):295-302
|
CSCD被引
8
次
|
|
|
|
|
3.
Petroulakis E. mTOR signaling: implications for cancer and anticancer therapy.
Br J Cancer,2006,94(2):195-199
|
CSCD被引
4
次
|
|
|
|
|
4.
Wang X. The mTOR Pathway in the Control of Protein Synthesis.
Physiology(Bethesda),2006,21(4):362-369
|
CSCD被引
25
次
|
|
|
|
|
5.
Sarbassov D D. Phosphorylation and regulation of AKT/PKB by the rictor/mTOR complex.
Science,2005,307(5712):1098-1101
|
CSCD被引
182
次
|
|
|
|
|
6.
Vignot S. mTOR-targeted therapy of cancer with rapamycin derivatives.
Ann Oncol,2005,16(4):525-537
|
CSCD被引
46
次
|
|
|
|
|
7.
庄莹. 雷帕霉素对人肺癌细胞株增殖抑制的研究.
广州医学院学报,2008,36(3):6-9
|
CSCD被引
2
次
|
|
|
|
|
8.
Noh W C. Determinants of rapamycin sensitivity in breast cancer cells.
Clin Cancer Res,2004,10(3):1013-1023
|
CSCD被引
15
次
|
|
|
|
|
9.
Nozawa H. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer.
Cancer Lett,2007,251(1):105-113
|
CSCD被引
9
次
|
|
|
|
|
了解气象卫星更多信息，请访问